Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 137240
Corporate User License Price USD 6000
Corporate User License Price INR 411720
Site License Price USD 4000
Site License Price INR 274480
Request a Quote

Report Title

Malignant Mesothelioma - Pipeline Review, H2 2018

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Malignant Mesothelioma - Pipeline Review, H2 2018


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Malignant Mesothelioma - Pipeline Review, H2 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Malignant Mesothelioma - Pipeline Review, H2 2018



Executive Summary

Malignant Mesothelioma-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 35, 33, 17, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 5, 5 and 8 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).

- The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 5

Malignant Mesothelioma-Overview 6

Malignant Mesothelioma-Therapeutics Development 7

Malignant Mesothelioma-Therapeutics Assessment 22

Malignant Mesothelioma-Companies Involved in Therapeutics Development 36

Malignant Mesothelioma-Drug Profiles 68

Malignant Mesothelioma-Dormant Projects 733

Malignant Mesothelioma-Discontinued Products 736

Malignant Mesothelioma-Product Development Milestones 737

Appendix 751

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Malignant Mesothelioma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

List of Tables

Number of Products under Development for Malignant Mesothelioma, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Malignant Mesothelioma-Pipeline by Advantagene Inc, H2 2018

Malignant Mesothelioma-Pipeline by Aldeyra Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Almac Discovery Ltd, H2 2018

Malignant Mesothelioma-Pipeline by AnGes Inc, H2 2018

Malignant Mesothelioma-Pipeline by Argenx SE, H2 2018

Malignant Mesothelioma-Pipeline by ArQule Inc, H2 2018

Malignant Mesothelioma-Pipeline by AstraZeneca Plc, H2 2018

Malignant Mesothelioma-Pipeline by Bayer AG, H2 2018

Malignant Mesothelioma-Pipeline by BerGenBio ASA, H2 2018

Malignant Mesothelioma-Pipeline by Biocad, H2 2018

Malignant Mesothelioma-Pipeline by Biogen Inc, H2 2018

Malignant Mesothelioma-Pipeline by Bionomics Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Biotecnol Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Boehringer Ingelheim GmbH, H2 2018

Malignant Mesothelioma-Pipeline by Boston Biomedical Inc, H2 2018

Malignant Mesothelioma-Pipeline by Bristol-Myers Squibb Co, H2 2018

Malignant Mesothelioma-Pipeline by Calithera Biosciences Inc, H2 2018

Malignant Mesothelioma-Pipeline by CanBas Co Ltd, H2 2018

Malignant Mesothelioma-Pipeline by CBT Pharmaceuticals Inc, H2 2018

Malignant Mesothelioma-Pipeline by Checkpoint Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Clovis Oncology Inc, H2 2018

Malignant Mesothelioma-Pipeline by Concordia International Corp, H2 2018

Malignant Mesothelioma-Pipeline by Eli Lilly and Co, H2 2018

Malignant Mesothelioma-Pipeline by EnGeneIC Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Epizyme Inc, H2 2018

Malignant Mesothelioma-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Malignant Mesothelioma-Pipeline by Genelux Corp, H2 2018

Malignant Mesothelioma-Pipeline by GlaxoSmithKline Plc, H2 2018

Malignant Mesothelioma-Pipeline by Horizon Pharma Plc, H2 2018

Malignant Mesothelioma-Pipeline by Incyte Corp, H2 2018

Malignant Mesothelioma-Pipeline by Infinity Pharmaceuticals Inc, H2 2018

Malignant Mesothelioma-Pipeline by Inventiva, H2 2018

Malignant Mesothelioma-Pipeline by Juno Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Karyopharm Therapeutics Inc, H2 2018

Malignant Mesothelioma-Pipeline by Laboratoires Pierre Fabre SA, H2 2018

Malignant Mesothelioma-Pipeline by MacroGenics Inc, H2 2018

Malignant Mesothelioma-Pipeline by MedImmune LLC, H2 2018

Malignant Mesothelioma-Pipeline by MELEMA Pharma GmbH, H2 2018

Malignant Mesothelioma-Pipeline by Merck & Co Inc, H2 2018

Malignant Mesothelioma-Pipeline by Merck KGaA, H2 2018

Malignant Mesothelioma-Pipeline by Millennium Pharmaceuticals Inc, H2 2018

Malignant Mesothelioma-Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018

Malignant Mesothelioma-Pipeline by MolMed SpA, H2 2018

Malignant Mesothelioma-Pipeline by Morphotek Inc, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Advantagene Inc

Aldeyra Therapeutics Inc

Almac Discovery Ltd

AnGes Inc

Argenx SE

ArQule Inc

AstraZeneca Plc

Bayer AG

BerGenBio ASA

Biocad

Biogen Inc

Bionomics Ltd

Biotecnol Ltd

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CanBas Co Ltd

CBT Pharmaceuticals Inc

Checkpoint Therapeutics Inc

Clovis Oncology Inc

Concordia International Corp

Eli Lilly and Co

EnGeneIC Ltd

Epizyme Inc

F. Hoffmann-La Roche Ltd

Genelux Corp

GlaxoSmithKline Plc

Horizon Pharma Plc

Incyte Corp

Infinity Pharmaceuticals Inc

Inventiva

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Laboratoires Pierre Fabre SA

MacroGenics Inc

MedImmune LLC

MELEMA Pharma GmbH

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

MolMed SpA

Morphotek Inc

MTG Biotherapeutics Inc

Novartis AG

Oasmia Pharmaceutical AB

Ono Pharmaceutical Co Ltd

Pharma Mar SA

Polaris Pharmaceuticals Inc

Seattle Genetics Inc

Selecta Biosciences Inc

SELLAS Life Sciences Group Inc

Sorrento Therapeutics Inc

Targovax ASA

TCR2 Therapeutics Inc

TESARO Inc

TRACON Pharmaceuticals Inc

TREAT U SA

VasGene Therapeutics Inc

Venus Remedies Ltd

Verastem Inc

Vyriad Inc

Y's Therapeutics Co Ltd

Malignant Mesothelioma Therapeutic Products under Development, Key Players in Malignant Mesothelioma Therapeutics, Malignant Mesothelioma Pipeline Overview, Malignant Mesothelioma Pipeline, Malignant Mesothelioma Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person